FDA: Cyramza approval now includes non-small-cell lung CA
(HealthDay)—U.S. Food and Drug Administration approval of the anti-cancer drug Cyramza (ramucirumab) has been expanded to include aggressive non-small-cell lung cancer (NSCLC), the agency said Friday.
Dec 14, 2014
0
0